Polymer–drug conjugates have long been a mainstay of the drug delivery field, with several
conjugates successfully translated into clinical practice. The conjugation of therapeutic …

Bone metastasis is the leading cause of death in prostate cancer patients, for which there is
currently no effective treatment. Since the bone microenvironment plays an important role in …

Target-site drug delivery systems are gaining interest in the pharmaceutical field due to their
great advantages, such as higher drug dosing capacity and better bioavailability. However …

The skeleton is affected by numerous primary and metastatic solid and hematopoietic
malignant tumors, which can cause localized sites of osteolysis or osteosclerosis that can …

Bone is the most common site of prostate cancer metastasis. Once prostate cancer cells
metastasize to bone, the mortality rate of prostate cancer patients increases significantly …

Metformin is a commonly used drug for the treatment of type II diabetes and atorvastatin is
the most prescribed cholesterol-lowering statin. The present study investigated the effects …

Aims This study aimed to assess the efficacy and safety of ODX, a novel, cytotoxic, bone-
targeting drug candidate, in castration-resistant prostate cancer bone metastatic disease …

Simple Summary Prostate cancer is the most common non-cutaneous malignancy among
men in the United States. Bone metastases and health are crucial issues in prostate cancer …

Polymers have been utilized to deliver drugs to the targeted site in a controlled manner and
for achieving high therapeutic efficacy. Polymer-drug conjugates having variable ligands …

Cancer has been a global challenge given the number of limitations of current therapies,
such as multi-drug resistance, high levels of toxicity, side effects, the tumor …